BRAF ^V600E mutated NSCLC: The evolving treatment landscape

In this short, animated video, lung cancer expert Prof. Amanda Tufman provides an overview of the clinical trial data and emerging profile of therapies for the treatment of BRAF^V600E mutated non-small cell lung cancer (NSCLC).

Prof. Tufman then moves on to highlight her views on the appropriate placement of therapies across the patient journey in the evolving treatment landscape.

The video is accompanied by a helpful slide set which provides more detail behind the key points addressed by Prof. Tufman. Find your slide set as a downloadable resource on this page.

Clinical takeaways

• BRAF^V600E is an actionable mutation for metastatic NSCLC with effective and well-tolerated treatment options available
• The BRAF mutation should be tested for at the time of first diagnosis for all patients with advanced NSCLC
• Only around half of patients with metastatic NSCLC receive a second-line treatment, so the most appropriate, efficacious treatments should be used in the first-line setting
• BRAF-targeted treatment combinations are approved for first-line treatment of NSCLC